D-0520-2016 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0520-2016 was initiated by Pfizer Inc. on Dec 2, 2015 and is designated Class III. Reason for recall: Failed Dissolution Specification The recall status is terminated (terminated Jul 26, 2017). Affected quantity: a) 4005 bottles, b) 104 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 16, 2015
Initiation Date
Dec 2, 2015
Termination Date
Jul 26, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 4005 bottles, b) 104 bottles

Product description

Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Reason for recall

Failed Dissolution Specification

Distribution pattern

Nationwide

Code information

Lot #: C150065; C150064, Exp 6/16

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0520-2016
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0520-2016. Report a data issue: hello@regdatalab.com.